איוואקיט 50 מ"ג - Ayvakit 50 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01EX Other protein kinase inhibitors | |||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | ×××××, TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 à 10^9/L. | |||||||||||||
| ||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | |||||||||||||
| ×ת××××ת × ×× | Contraindications | |||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | |||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | |||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | |||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | |||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×××××ק×× 50 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BLUEPRINT MEDICINES CORPORATION , USA |
| ×©× ××¢× ×ר×ש×× | NEOPHARM (ISRAEL) 1996 LTD |
| ר×ש××× | ת×ר×× ××ש×: 6/2021. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 17/08/2024 |
השינוי האחרון נעשה בֹ־17 באוגוסט 2024 ב־06:36